ruthenium tetraoxide has been researched along with Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ivastinovic, D; Langmann, G; Schneider, M; Tarmann, L; Wackernagel, W; Winkler, P | 1 |
| Frenkel, S; Hendler, K; Kaiserman, I; Kaiserman, N; Pe'er, J | 1 |
2 other study(ies) available for ruthenium tetraoxide and Melanoma
| Article | Year |
|---|---|
Tumor parameters predict the risk of side effects after ruthenium-106 plaque brachytherapy of uveal melanomas.
Topics: Adult; Aged; Aged, 80 and over; Brachytherapy; Cataract; Eye; Female; Humans; Male; Melanoma; Middle Aged; Optic Nerve Diseases; Retinal Detachment; Ruthenium Compounds; Uveal Neoplasms; Visual Acuity; Vitreous Hemorrhage | 2017 |
Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas.
Topics: Brachytherapy; Eye Enucleation; Female; Humans; Kaplan-Meier Estimate; Male; Melanoma; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Ruthenium Compounds; Treatment Outcome; Uveal Neoplasms; Visual Acuity | 2009 |